Exploring the Application Value of PET Molecular Imaging Targeting FAP in Oral Squamous Cell Carcinoma
Status:
Not yet recruiting
Trial end date:
2023-12-31
Target enrollment:
Participant gender:
Summary
Positron emission tomography (PET) molecular imaging provides a valuable method for the
diagnosis, differential diagnosis and staging of various tumors. Cancer associated
fibroblasts (CAFs) are the main components of tumor stroma, which are involved in tumor cell
proliferation, invasion, metastasis and tumor angiogenesis, and play an important role in the
occurrence and development of tumors. Fibroblast activation protein (FAP) is the most
potential specific molecular marker of CAF, which is mainly expressed in stromal fibroblasts
of epithelial tumors and is a potential molecular target for tumor diagnosis and treatment.
Oral cancer is the most common type of malignant head and neck cancer, seriously endangering
human health. Accurate delineation of the primary tumor, detection of regional nodal
metastases, distant metastases and second primary tumors are important for determining the
therapeutic strategy and prognosis of oral cancer. Currently, the molecular imaging agent
most commonly used in clinical practice for oral cancer is 18F-fluoro-deoxy-glucose
(18F-FDG). However, 18F-FDG exhibits some shortages. Inflammatory lesions and the surrounding
normal tissue such as brain, tonsils and salivary glands show high uptake of 18F-FDG, often
affecting the judgment of lesions. In this prospective study, the investigators will use
integrated PET/CT with the agent 68Ga-FAPI and conventional imaging agent 18F-FDG to explore
the application value of FAP-targeted molecular imaging in the diagnosis and staging for oral
cancer.